Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | PPID | Q08752 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10597046 | 0.88 | RAB9A (0.49) | ALDH1A1SMN1; SMN2KDM4EMAPTLTA4H | |
| SCHEMBL13222646 | 0.87 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2KDM4EMAPTLTA4H | |
| SCHEMBL3184733 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTLTA4HLMNA | |
| SCHEMBL29304528 | 0.85 | LTA4H (0.55) | ALDH1A1SMN1; SMN2KDM4EMAPTLTA4H | |
| SCHEMBL254781 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MAPTLTA4HLMNA | |
| SCHEMBL10076568 | 0.84 | KMT2A (0.49) | ALDH1A1SMN1; SMN2KDM4EMAPTLTA4H | |
| SCHEMBL3147669 | 0.84 | PPID (0.50) | ALDH1A1SMN1; SMN2KDM4EMAPTLTA4H | |
| SCHEMBL1303146 | 0.84 | LTA4H (0.62) | ALDH1A1SMN1; SMN2LTA4HLMNAPOLB | |
| SCHEMBL5941081 | 0.83 | PIN1 (0.56) | ALDH1A1SMN1; SMN2LTA4HLMNAPOLB | |
| SCHEMBL5761072 | 0.83 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| EP-3562811-B1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S L (ES) | 2022-03-16 | — | — | EP | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2019-11-07 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| WO-2004093860-A1 | INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-0020018-B1 | CHROMAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1983-06-01 | — | — | EP | disclosed |
| US-4303656-A | ANOREXIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | ALDH1A1 2888/4885SMN1; SMN2 4282/4885KDM4E 535/4885 |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | ALDH1A1 710/4885SMN1; SMN2 432/4885KDM4E 3069/4885 |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | ALDH1A1 1097/4885SMN1; SMN2 36/4885KDM4E 4446/4885 |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | ALDH1A1 1097/4885SMN1; SMN2 36/4885KDM4E 4446/4885 |
| US-11174242-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | ALDH1A1 1097/4885SMN1; SMN2 36/4885KDM4E 4446/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | ALDH1A1 1097/4885SMN1; SMN2 36/4885KDM4E 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.